Abbott announced on November 10 that it holds both FDA approval and a CE mark for UltiSynq, a defibrillation lead placed in the left bundle branch area. The lead also carries an FDA breakthrough device designation. It is meant for patients who need conduction system pacing and defibrillation protection from the same system.

The approvals rest on the ASCEND CSP IDE study, a prospective global trial in candidates for an ICD or a CRT-D. Implantation succeeded in 98.5 percent of 205 attempts, with fewer than one repositioning attempt on average. Of patients implanted successfully, 86 percent achieved left bundle branch pacing or likely left bundle branch pacing, and the other 14 percent had left ventricular septal pacing. The three-month major complication-free rate was 97.5 percent. All 120 patients who completed defibrillation testing were defibrillated without repositioning the lead.

Conduction system pacing has moved quickly on the pacing side and slowly on the defibrillation side, because a lead in the left bundle branch area has to deliver a shock as well as pace. Abbott says true bipolar sensing on UltiSynq should also cut P-wave oversensing. Medtronic took a CE mark for five conduction system pacing pacemakers in October, which puts two large portfolios in the same territory inside a month.